Home › All Companies › AIM

AIM ImmunoTech Inc. (AIM)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-10

Key Insights

  • AIM ImmunoTech has entered into an amendment to its existing Equity Distribution Agreement with Maxim Group LLC, removing the limitation on the amount of shares that can be sold under the at-the-market public offering.
  • The company is filing a supplement to the prospectus supplement to increase the number of shares that may be offered and sold in the at-the-market public offering.
  • This indicates that AIM ImmunoTech is seeking to raise additional capital through the sale of its common stock, which could be used for various corporate purposes.
Sentiment: Positive Significance: 7/10
View Original Filing →
Annual Report Filed: 2026-03-27

Key Insights

  • The company has experienced significant growth in its patent and trademark portfolio, indicating potential for future value creation.
  • The company has entered into several financing agreements with Streeterville Capital, LLC which provide additional capital to fund operations.
  • The company has implemented an employee stock purchase plan, which could help with talent retention and alignment with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-16

Key Insights

  • The reporting person, David I. Chemerow, is a director of AIM ImmunoTech Inc. and acquired 25,000 shares of the company's common stock through the conversion of 25 shares of Series G Convertible Preferred Stock.
  • The transaction was executed on March 12, 2026, and Chemerow now beneficially owns a total of 28,441 shares of the company's common stock.
  • The conversion of preferred shares into common stock at a rate of 1,000 shares per preferred share suggests the company is providing director compensation in the form of equity.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-03-16

Key Insights

  • The CEO and President, Thomas K. Equels, acquired 25,000 shares of common stock through the conversion of 25 shares of Series G Convertible Preferred Stock, indicating his confidence in the company's future.
  • The exercise price for the conversion of the preferred shares to common shares was $0, effectively allowing Equels to acquire the shares at a significant discount.
  • Equels now holds a direct ownership of 63,922 shares of common stock, suggesting his alignment with shareholders and long-term commitment to the company.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-03-06

Key Insights

  • AIM ImmunoTech Inc. has filed a Certificate of Designation to create a new series of preferred stock, the Series G Convertible Preferred Stock, which can be converted into common stock at a price of $1.00 per share.
  • The company has completed a rights offering, selling 1,842 units consisting of Series G Preferred Stock and Class G Warrants, raising gross proceeds of approximately $1.8 million.
  • The Series G Preferred Stock has certain conversion limitations, anti-dilution provisions, and liquidation preferences that investors should be aware of.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-06

Key Insights

  • David Chemerow, a director of AIM ImmunoTech Inc., acquired 2,800 shares of the company's common stock at $1.23 per share, indicating insider buying activity.
  • The acquisition increased Chemerow's beneficial ownership in the company, with a total of 3,441 shares now held indirectly through The David I Chemerow 1992 Trust.
  • Insider buying can signal management's confidence in the company's prospects and may be a positive indicator for investors.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-02-05

Key Insights

  • AIM ImmunoTech is conducting a Phase I/II open-label study of Durvalumab (Imfinzi) and Rintatolimod (Ampligen) in pancreatic cancer patients with stable disease post-FOLFIRINOX treatment.
  • The company has provided an interim clinical progress update on the DURIPANC study, indicating ongoing activities and developments.
  • AIM has furnished its February 2026 corporate presentation, which likely contains additional details on the company's strategic initiatives and pipeline progress.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-01-20

Key Insights

  • AIM ImmunoTech is making changes to its Class E and Class F common stock purchase warrants, potentially impacting shareholders.
  • The company is involved in multiple clinical trials evaluating its drug Ampligen for the treatment of viral diseases, cancers, and immune-deficiency disorders, though no assurances are given regarding the outcomes.
  • The filing includes cautionary statements regarding forward-looking statements and risk factors that investors should review carefully.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.